This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Troughton, R. W. Articles by Nicholls, M. G. Search for Related Content PubMed PubMed Citation Articles by Troughton, R. W. Articles by Nicholls, M. G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB EPINEPHRINE HYDROCORTISONE POTASSIUM SODIUM Medline Plus Health Information High Blood Pressure

(Hypertension. 2000;36:588.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Hemodynamic, Hormone, and Urinary Effects of Adrenomedullin Infusion in Essential Hypertension

Richard W. Troughton; Lynley K. Lewis; Timothy G. Yandle; A. Mark Richards; M. Gary Nicholls

From the Christchurch Cardioendocrine Research Group, Christchurch Hospital and Christchurch School of Medicine, Christchurch, New Zealand.

Correspondence to Dr Richard Troughton, Department of Medicine, Christchurch Hospital, PO Box 4345, Riccarton Ave, Christchurch, New Zealand. E-mail richard.troughton{at}chmeds.ac.nz

Abstract—We examined the effects of the vasodilator peptide adrenomedullin (AM) infused intravenously into subjects with essential hypertension. Eight men 39 to 58 years old with uncomplicated hypertension (147/96±5/3 mm Hg at baseline) were studied in a placebo-controlled, crossover design. Each subject received intravenous AM in a low and a high dose (2.9 and 5.8 pmol · kg^-1 · min^-1 for 2 hours each) or vehicle-control (Hemaccel) infusion in a random order on day 4 of a controlled metabolic diet (80 mmol/d Na⁺, 100 mmol/d K⁺). Plasma AM reached pathophysiological levels during infusion (18±4 pmol/L in low dose, 34±9 pmol/L in high dose) with a concurrent rise in plasma cAMP (+8.4±1.2 pmol/L, P<0.05 compared with control). Compared with control, high-dose AM increased peak heart rate (+17.8±2.3 bpm, P<0.01), lowered systolic (-24.6±0.9 mm Hg; P<0.01) and diastolic (-21.9±1.4 mm Hg; P<0.01) blood pressure, and increased cardiac output (+1.0±0.1 L/min in low dose, +2.9±0.2 L/min in high dose; P<0.01 for both). Despite a rise in plasma renin activity during high dose (P<0.05), aldosterone levels did not alter. Plasma norepinephrine levels increased 1295±222 pmol/L (P<0.001) and epinephrine increased 74±15 pmol/L (P<0.05) with high-dose AM compared with control. AM had no significant effect on urine volume and sodium excretion. In subjects with essential hypertension, the intravenous infusion of AM to achieve pathophysiological levels produced significant falls in arterial pressure, increased heart rate and cardiac output, and stimulated the sympathetic system and renin release without concurrent increase in aldosterone. Urinary parameters were unaltered. Although AM has potent hemodynamic and neurohumoral effects in subjects with essential hypertension, the threshold for urinary actions is set higher.

Key Words: hypertension, essential • adrenomedullin • renin • nervous system, sympathetic • blood pressure • cardiac output

This article has been cited by other articles:

				J. P. Chute, E. Taylor, J. Williams, F. Kaye, D. Venzon, and B. E. Johnson A Metabolic Study of Patients with Lung Cancer and Hyponatremia of Malignancy Clin. Cancer Res., February 1, 2006; 12(3): 888 - 896. [Abstract] [Full Text] [PDF]

				C J Charles, D L Jardine, M G Nicholls, and A M Richards Adrenomedullin increases cardiac sympathetic nerve activity in normal conscious sheep J. Endocrinol., November 1, 2005; 187(2): 275 - 281. [Abstract] [Full Text] [PDF]

				S. D. Brain and A. D. Grant Vascular Actions of Calcitonin Gene-Related Peptide and Adrenomedullin Physiol Rev, July 1, 2004; 84(3): 903 - 934. [Abstract] [Full Text] [PDF]

				J. Roh, C. L. Chang, A. Bhalla, C. Klein, and S. Y. T. Hsu Intermedin Is a Calcitonin/Calcitonin Gene-related Peptide Family Peptide Acting through the Calcitonin Receptor-like Receptor/Receptor Activity-modifying Protein Receptor Complexes J. Biol. Chem., February 20, 2004; 279(8): 7264 - 7274. [Abstract] [Full Text] [PDF]

				C. V. Maniu, D. M. Meyer, and M. M. Redfield Hemodynamic and Humoral Effects of Vasopeptidase Inhibition in Canine Hypertension Hypertension, October 1, 2002; 40(4): 528 - 534. [Abstract] [Full Text] [PDF]

				Y. Mori, T. Nishikimi, N. Kobayashi, H. Ono, K. Kangawa, and H. Matsuoka Long-Term Adrenomedullin Infusion Improves Survival in Malignant Hypertensive Rats Hypertension, July 1, 2002; 40(1): 107 - 113. [Abstract] [Full Text] [PDF]

				C. Letizia, S. Subioli, S. Cerci, C. Caliumi, C. Verrelli, E. Delfini, M. Celi, L. Scuro, and E. D'Erasmo High plasma adrenomedullin concentrations in patients with high-renin essential hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 126 - 129. [Abstract] [PDF]

				T. Shimosawa, Y. Shibagaki, K. Ishibashi, K. Kitamura, K. Kangawa, S. Kato, K. Ando, and T. Fujita Adrenomedullin, an Endogenous Peptide, Counteracts Cardiovascular Damage Circulation, January 1, 2002; 105(1): 106 - 111. [Abstract] [Full Text] [PDF]

				D. O. McGregor, R. W. Troughton, C. Frampton, K. L. Lynn, T. Yandle, A. M. Richards, and M. G. Nicholls Hypotensive and Natriuretic Actions of Adrenomedullin in Subjects With Chronic Renal Impairment Hypertension, May 1, 2001; 37(5): 1279 - 1284. [Abstract] [Full Text] [PDF]